3 results
Primairy objective: Does the use of daily magnesium oxide reduce the prostate movements during a radiotherapy fraction? Secondary objectives: Does the use of magnesium oxide change the acute toxicity of the treatment? Does the use of magnesium oxide…
Primary:To investigate the safety and tolerability of 60 mg 3 times daily doses of GSK2982772 in subjects with moderate to severe ulcerative colitis.Secondary:To assess the preliminary efficacy, biomarkers, histological disease activity, response…
Primary: To compare the pharmacokinetics (PK) of the once daily (QD) and once weekly (QW) formulations of setmelanotideSecondary Objectives:To assess the safety of the QW formulation of setmelanotide with up to 6 months (26 weeks) of drug…